Precision Medicine in Oncology

Building a Patient-Centered Cancer Center From the Ground Up

October 13th 2021, 2:17pm


More Data Needed on Tissue-Agnostic Therapy Use in Breast Cancer

October 12th 2021, 4:45pm


This new study concluded that the breast cancer space needs more data to evaluate if there is a place for tissue-agnostic treatments for these patients.

Study Probes Role of Epigenetics in Precision Medicine for Lung Cancer

October 11th 2021, 8:45pm


New modeling could help explain why some patients develop resistance to tyrosine kinase inhibitors.

The Promise of Liquid Biopsies for Cancer Diagnosis

October 11th 2021, 12:00pm


Providing Patients With Cancer Access to Affordable Housing During Treatment

October 7th 2021, 4:00pm


Patients traveling for cancer treatment often incur financial burdens. The members of the Alliance of Dedicated Cancer Centers should play a role in mitigating housing-associated costs for patients during cancer treatment.

Abstracts at ASCO Quality Show Uptake of Rapid NGS, Biomarker Testing Across OneOncology

October 4th 2021, 1:30pm


Using AI to Predict Outcomes in High-grade Extrauterine Serous Carcinoma

October 1st 2021, 5:00pm


MRD Monitoring Useful Across Risk Groups in ALL

September 23rd 2021, 3:15pm


In a recent paper, researchers outlined the utility of minimal residual disease (MRD) among patient with acute lymphoblastic leukemia (ALL) and how its monitoring at specific timepoints has proven useful for stratifying patients and helping to ensure appropriate treatment decisionsMRD

Researchers Outline Ongoing Potential of ctDNA Analysis in GEA

September 19th 2021, 5:40pm


Unlike the success seen in other cancer types, biomarker-driven treatment advances in gastroesophageal adenocarcinoma (GEA) have been hindered by its genomic heterogeneity. A significant proportion of patients also develop resistant subclones through selective pressure, resulting in disease progression.

Phase 3 Data Solidify Cemiplimab’s Role in Second-Line Treatment of Cervical Cancer

September 18th 2021, 1:10pm


In May, results showed that cemiplimab (Libtayo, Regeneron/Sanofi) produced significant benefits: a 31% reduction in the risk of death and a 25% reduction in the risk of disease progression.